Research Park at Florida Atlantic University® Based FloSpine Successfully Implants First Ti-Largo 3D Printed Cervical Cage

Recently Cleared Device Patient-Centrically Designed, Enhances Osseointegration and Biocompatibility

Together with FloSpine, the Research Park at Florida Atlantic University® is pleased to announce the successful implantation of the Ti-Largo 3D Printed Cervical Cage, a groundbreaking advancement in the field of spinal surgery. The Ti-Largo Cervical Cage is designed to seamlessly complement the already FDA-cleared Panama Anterior Cervical Plate, creating a comprehensive solution for cervical spine procedures.

The Ti-Largo 3D Printed Cervical Cage represents a significant milestone in FloSpine’s commitment to developing cutting-edge spinal solutions that improve patient outcomes and enhance the capabilities of surgeons. This revolutionary cervical cage leverages 3D printing technology to deliver a highly customizable, patient-specific implant that enables minimally invasive cervical spine surgery.

Key features of the Ti-Largo 3D Printed Cervical Cage include:

  • Patient-Centric Design: Each Ti-Largo cervical cage is designed to meet the unique anatomical needs of the patient. This personalized approach ensures a precise fit and optimized spinal stability.
  • Enhanced Biocompatibility: The Ti-Largo cage is 3D printed from a high-grade titanium alloy known for its excellent biocompatibility, corrosion resistance, and strength. This material minimizes the risk of adverse reactions and offers long-term durability.
  • Minimally Invasive Surgery: The Ti-Largo implant is designed for minimally invasive cervical spine surgery, reducing tissue disruption, post-operative pain, and recovery time for patients.
  • Optimized Osseointegration: The porous structure of the Ti-Largo cage facilitates bone ingrowth, promoting fusion and long-term stability.

The FDA clearance of the Ti-Largo 3D Printed Cervical Cage underscores FloSpine’s commitment to adhering to the highest regulatory standards and its dedication to delivering innovative solutions to patients and healthcare providers.

Inaugurating this momentous occasion, Dr. John Afshar, a renowned spinal surgeon at Palm Beach Neuroscience Institute successfully implanted the Ti-Largo 3D Printed Cervical Cage in the first patients earlier this month. Dr. Afshar shared, “The Ti-Largo cervical cage represents a major leap forward in cervical spine surgery. Its patient-specific design and 3D printing technology have the potential to revolutionize the way we approach these procedures, offering greater precision and improved outcomes for our patients.”

The Ti-Largo 3D Printed Cervical Cage couples with FloSpine’s Panama Anterior Cervical Plate, which received FDA clearance in 2021. This combination provides surgeons with a comprehensive solution for anterior cervical spine surgery, ensuring stability, alignment, and long-term fusion.

FloSpine CEO, Peter Harris, expressed pride and optimism for the future, stating, “The successful implantations of the Ti-Largo 3D Printed Cervical Cage, in conjunction with the Panama Anterior Cervical Plate, are a testament to the dedication and ingenuity of our team. We are excited about the positive impact this innovation will have on patients’ lives.”

FloSpine is actively collaborating with medical professionals, hospitals, and healthcare institutions to introduce the Ti-Largo Cervical Cage and Panama Anterior Cervical Plate to a broader patient population. This next generation technology has the potential to transform the landscape of cervical spine surgery, providing new hope and improved outcomes for those suffering from cervical spine conditions.

FloSpine has benefited from the support and assistance of the Global Ventures second-stage company incubator as it has grown. Dialogue and interaction with Florida Atlantic University’s faculty spurred innovation in the material design, executed by graduates of FAU’s College of Engineering and Computer Science.

“FloSpine’s growth and development demonstrates that Global Ventures is effective at growing companies in Palm Beach County with local residents and resources. The benefits are felt across the community and over the years,” commented Andrew S. Duffell, president of the Research Park at FAU. “We congratulate the innovation and focus of the FloSpine team.”

FloSpine expects to move from the Global Ventures incubator into the Research Park itself in the coming months, to accommodate its long-term growth in close proximity to its support network.

 

SourceFloSpine

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version